Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

KRAS in the clinic and conference

ESMO 2016

7 - 11 Oct 2016

Published: 9 Oct 2016

Views: 2140

Rating:

Save

Dr Ana Vivancos - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Dr Vivancos meets with ecancertv at ESMO 2016 to discuss how her lab is targeting KRAS mutations, with liquid biopsies guiding research.

She discusses clinical practice, working with lung adenocarcinomas, metastatic colorectal cancer and pancreatic cancer, and the opportunities of collaboration and professional development through the conference.

Considering the news from ESMO so far, Dr Vivancos anticipates novel biomarkers and immunotherapy having a significant influence over future standards of care.

Related Videos

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

A biomarker led approach to bladder cancer

Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr...

A biomarker led approach to bladder cancer ( Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr Yohann Loriot )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic...

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City...

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

Choosing Wisely in radiology Tanzania

Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in radiology Tanzania ( Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC...

Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )

Latest in PARP inhibitors and combination therapies for prostate cancer

Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni...

Latest in PARP inhibitors and combination therapies for prostate cancer ( Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni Efstathiou )

Overview of the management of HER2-low breast cancer patients

Prof Hope Rugo - University of California San Francisco, San Francisco, USA

Overview of the management of HER2-low breast cancer patients ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )

Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis...

Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio...

Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor ( Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )

EGFR testing: Best practice for NSCLC patients with exon 20 insertions

Dr Antonio Passaro, Dr Umberto Malapelle and Dr Joshua Sabari

EGFR testing: Best practice for NSCLC patients with exon 20 insertions ( Dr Antonio Passaro, Dr Umberto Malapelle and Dr Joshua Sabari )

More from ecancer